fda semaglutide compounding enforcement october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our New Study Finds Compounded GLP-1s

Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/Akt-dependent and MAPK/CREB-independent

10,11 Clinical photographs were taken with patients consent in identical settings and lighting at every follow-up before successive sessions

Given that the GLP1 receptor is expressed on all four chambers of the heart as well as the sinoatrial node, it is likely that GLP1 and its mimetics exert a direct action on cardiac cells (Baggio et al., 2018)

In another animal study, ashwagandha reversed paclitaxel-induced neutropenia in mice when administered for four days before paclitaxel treatment and continued for 12 days after treatment